Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Whitehawk Therapeutics (WHWK) Debt to Equity: 2020-2021

  • Whitehawk Therapeutics' Debt to Equity rose 103.83% to $0.04 in Q4 2021 from the same period last year, while for Dec 2021 it was $0.04, marking a year-over-year increase of 103.83%. This contributed to the annual value of $0.04 for FY2021, which is 103.83% up from last year.
  • According to the latest figures from Q4 2021, Whitehawk Therapeutics' Debt to Equity is $0.04, which was up 15.16% from $0.04 recorded in Q3 2021.
  • Whitehawk Therapeutics' 5-year Debt to Equity high stood at $0.04 for Q4 2021, and its period low was -$1.15 during Q4 2020.
  • Over the past 2 years, Whitehawk Therapeutics' median Debt to Equity value was $0.04 (recorded in 2021), while the average stood at -$0.36.
  • Data for Whitehawk Therapeutics' Debt to Equity shows a peak YoY skyrocketed of 103.83% (in 2021) over the last 5 years.
  • Whitehawk Therapeutics' Debt to Equity (Quarterly) stood at -$1.15 in 2020, then soared by 103.83% to $0.04 in 2021.
  • Its Debt to Equity stands at $0.04 for Q4 2021, versus $0.04 for Q3 2021 and -$1.15 for Q4 2020.